{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:01:10Z","timestamp":1774886470086,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.vaccine.2003.10.042","type":"journal-article","created":{"date-parts":[[2004,1,23]],"date-time":"2004-01-23T10:18:57Z","timestamp":1074853137000},"page":"3349-3355","source":"Crossref","is-referenced-by-count":43,"title":["Cost\u2013benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes\u2013zoster epidemiology"],"prefix":"10.1016","volume":"23","author":[{"given":"G.S.","family":"Goldman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11\/12","key":"10.1016\/j.vaccine.2003.10.042_BIB1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0264-410X(02)00431-0","article-title":"The cost-effectiveness of routine childhood varicella vaccination in Germany","volume":"21","author":"Banz","year":"2003","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2003.10.042_BIB2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0272989X02239651","article-title":"Economic evaluation of vaccination programs: the impact of herd-immunity","volume":"23","author":"Brisson","year":"2003","journal-title":"Med Decis Making"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2003.10.042_BIB3","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1093\/infdis\/174.Supplement_3.S335","article-title":"Costs and benefits of routine varicella vaccination in German children","volume":"174","author":"Beutels","year":"1996","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2003.10.042_BIB4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0264-410X(98)00161-3","article-title":"The value of varicella vaccination in healthy children: cost\u2013benefit analysis of the situation in France","volume":"17","author":"Coudeville","year":"1999","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2003.10.042_BIB5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/00006454-200206000-00012","article-title":"Instituting a routine varicella vaccination program in Canada: an economic evaluation","volume":"21","author":"Getsios","year":"2002","journal-title":"Pediatr Infec Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2003.10.042_BIB6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0891-5520(05)70318-4","article-title":"Epidemiologic effects of varicella vaccination","volume":"10","author":"Holloran","year":"1996","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB7","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0022-3476(05)83173-7","article-title":"Childhood vaccination against chickenpox: an analysis of benefits and costs","volume":"124","author":"Huse","year":"1994","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/clinids\/17.3.441","article-title":"An economic evaluation of varicella vaccine for pediatric liver and kidney transplant recipients","volume":"17","author":"Kitai","year":"1993","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2003.10.042_BIB9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jama.271.5.375","article-title":"Cost-effectiveness of a routine varicella vaccination program for US children","volume":"271","author":"Lieu","year":"1994","journal-title":"JAMA"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2003.10.042_BIB10","first-page":"17","article-title":"A benefit-cost analysis of childhood varicella vaccination programme","volume":"61","author":"Preblud","year":"1985","journal-title":"Postgrad Med J"},{"issue":"4 Pt2","key":"10.1016\/j.vaccine.2003.10.042_BIB11","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1542\/peds.78.4.728","article-title":"Varicella: complications and costs","volume":"78","author":"Preblud","year":"1986","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB12","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1086\/338956","article-title":"Do the benefits of varicella vaccination outweigh the longer-term risks? A decision-analytic model for policy makers and pediatricians","volume":"24","author":"Rothberg","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0277-9536(99)00115-X","article-title":"The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunization schedule","volume":"49","author":"Scuffham","year":"1999","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0264-410X(99)00261-3","article-title":"The cost effectiveness of varicella vaccine programs for Australia","volume":"18","author":"Scuffham","year":"1999","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2003.10.042_BIB15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00019053-200321010-00002","article-title":"Economic evaluations of varicella vaccination programmes: a review of the literature","volume":"21","author":"Thiry","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"7\/8","key":"10.1016\/j.vaccine.2003.10.042_BIB16","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0264-410X(01)00437-6","article-title":"The cost effectiveness of varicella vaccination in Canada","volume":"20","author":"Brisson","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB17","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1016\/S0264-410X(01)00044-5","article-title":"The epidemiology of herpes\u2013zoster and potential cost-effectiveness of vaccination in England and Wales","volume":"19","author":"Edmunds","year":"2001","journal-title":"Vaccine"},{"issue":"27\/30","key":"10.1016\/j.vaccine.2003.10.042_BIB18","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1016\/S0264-410X(03)00459-6","article-title":"Incidence of herpes\u2013zoster among children and adolescents in a community with moderate varicella vaccination coverage","volume":"21","author":"Goldman","year":"2003","journal-title":"Vaccine"},{"issue":"19\/20","key":"10.1016\/j.vaccine.2003.10.042_BIB19","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/S0264-410X(02)00180-9","article-title":"Exposure to varicella boosts immunity to herpes\u2013zoster: implications for mass vaccination against chickenpox","volume":"20","author":"Brisson","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB20","doi-asserted-by":"crossref","unstructured":"Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes\u2013zoster in adults: a case\u2013control study. Lancet 2002. http:\/\/image.thelancet.com\/extras\/01art6088web.pdf.","DOI":"10.1016\/S0140-6736(02)09837-9"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB21","unstructured":"Skull SA, Wang EEL, Canadian Task Force on Preventive Health Care. Use of varicella vaccine in healthy populations: systematic review and recommendations. CTFPHC Technical Report #01-1. London, ON: Canadian Task Force; 2000."},{"key":"10.1016\/j.vaccine.2003.10.042_BIB22","first-page":"9","article-title":"The nature of herpes\u2013zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/infdis\/148.2.200","article-title":"Immunologic evidence of reinfection with varicella\u2013zoster virus","volume":"148","author":"Arvin","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0190-9622(98)70207-5","article-title":"Lasting immunity to varicella in doctors study (L.I.V.I.D. study)","volume":"38","author":"Solmon","year":"1998","journal-title":"Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.vaccine.2003.10.042_BIB25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.11150\/kansenshogakuzasshi1970.69.908","article-title":"Incidence of herpes\u2013zoster in pediatricians and history of reexposure to varicella\u2013zoster virus in patients with herpes\u2013zoster","volume":"69","author":"Terada","year":"1995","journal-title":"Kansenshogaku Zasshi"},{"issue":"5","key":"10.1016\/j.vaccine.2003.10.042_BIB26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.287.5.606","article-title":"Varicella disease after introduction of varicella vaccine in the United States, 1995\u20132000","volume":"287","author":"Seward","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB27","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/archinte.155.15.1605","article-title":"The incidence of herpes\u2013zoster","volume":"155","author":"Donahue","year":"1995","journal-title":"Arch Intern Med"},{"issue":"suppl 8","key":"10.1016\/j.vaccine.2003.10.042_BIB28","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1212\/WNL.45.12_Suppl_8.S41","article-title":"Immunization to reduce the frequency and severity of herpes\u2013zoster and its complications","volume":"45","author":"Oxman","year":"1995","journal-title":"Neurology"},{"issue":"27\/30","key":"10.1016\/j.vaccine.2003.10.042_BIB29","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1016\/S0264-410X(03)00461-4","article-title":"Varicella susceptibility and incidence of herpes\u2013zoster among children and adolescents in a community under active surveillance","volume":"21","author":"Goldman","year":"2003","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2003.10.042_BIB30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3928\/0090-4481-19980701-11","article-title":"Vaccine safety: current and future challenges","volume":"27","author":"Chen","year":"1998","journal-title":"Pediatric Ann"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1017\/S0950268800004714","article-title":"Modelling the impact of immunization on the epidemiology of varicella\u2013zoster virus","volume":"125","author":"Brisson","year":"2000","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00013542-199310000-00006","article-title":"Epidemiology, outcome and control of varicella infection","volume":"4","author":"Miller","year":"1993","journal-title":"Rev Med Microbiol"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB33","unstructured":"Direct costs attributed to chickenpox and herpes zoster in British Columbia 1992 to 1996, Canada Communicable Disease Report (CCDR), June 1, 1999;25(11):100\u20134."},{"issue":"2","key":"10.1016\/j.vaccine.2003.10.042_BIB34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/aje\/154.2.161","article-title":"Prevalence of antibodies to four herpes viruses among adults with glioma and controls","volume":"154","author":"Wrensch","year":"2001","journal-title":"Am J Epidem"},{"issue":"1","key":"10.1016\/j.vaccine.2003.10.042_BIB35","first-page":"59","article-title":"Monitoring virus strain variation following infection with VZV: is there a need and what are the implications of introducing the Oka vaccine?","volume":"6","author":"Breuer","year":"2003","journal-title":"Commun Dis Public Health"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB36","first-page":"576","article-title":"Surveillance of viral pathogens in Australia\u2013varicella-zoster virus","volume":"26","author":"Roche","year":"2002","journal-title":"Commun Dis Intell"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB37","unstructured":"National Center for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS), NCIRS Newsletter, 2002 Dec. 3. Available from: http:\/\/www.ncirs.usyd.edu.au\/newsltrs\/newsletter_01.pdf."},{"key":"10.1016\/j.vaccine.2003.10.042_BIB38","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1001\/jama.287.17.2211","article-title":"Varicella vaccine and shingles","volume":"287","author":"Seward","year":"2002","journal-title":"[Letter] JAMA"},{"key":"10.1016\/j.vaccine.2003.10.042_BIB39","unstructured":"Maupin TJ, Goldman GS, Peterson CL, Mascola L. 2002 Annual Summary, Varicella Surveillance Project, Los Angeles County Department of Health Services (LACDHS); CDC Cooperative, 2002 Agreement No.: U66\/CCU911165-10."},{"key":"10.1016\/j.vaccine.2003.10.042_BIB40","unstructured":"Ray P, Zhang L, Lewis E, Shinefield H, Black S. A comparison of pre and post varicella vaccine licensure hospitalization rates for varicella and herpes zoster. In: Weddle A, ed. Proceedings of the 3rd International Pediatric Infectious Disease Conference, Monterey, CA. Alexandria, VA: Paediatric Infectious Diseases Society, 2001;136."},{"key":"10.1016\/j.vaccine.2003.10.042_BIB41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/geront\/41.2.201","article-title":"American grandparents providing extensive childcare to their grandchildren: prevalence and profile","volume":"41","author":"Fuller-Thomson","year":"2001","journal-title":"Gerentologist"},{"issue":"3","key":"10.1016\/j.vaccine.2003.10.042_BIB42","first-page":"185","article-title":"Varicella vaccination: a double-edged sword?","volume":"5","author":"Edmunds","year":"2002","journal-title":"Commun Dis Public Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X03008776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X03008776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T19:36:38Z","timestamp":1682624198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X03008776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":42,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0264410X03008776"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2003.10.042","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}